| dc.contributor.author | Parker, C | |
| dc.date.accessioned | 2018-01-24T15:06:48Z | |
| dc.date.issued | 2018-02 | |
| dc.identifier.citation | European urology, 2018, 73 (2), pp. 304 - ? | |
| dc.identifier.issn | 0302-2838 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1022 | |
| dc.identifier.eissn | 1873-7560 | |
| dc.identifier.doi | 10.1016/j.eururo.2017.11.007 | |
| dc.format | Print-Electronic | |
| dc.format.extent | 304 - ? | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.subject | Humans | |
| dc.subject | Bone Neoplasms | |
| dc.subject | Diphosphonates | |
| dc.subject | Imidazoles | |
| dc.subject | Bone Density Conservation Agents | |
| dc.title | Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2017-11-09 | |
| rioxxterms.versionofrecord | 10.1016/j.eururo.2017.11.007 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2018-02 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | European urology | |
| pubs.issue | 2 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 73 | |
| pubs.embargo.terms | Not known | |
| dc.contributor.icrauthor | Parker, Chris | |
| dc.contributor.icrauthor | Marsden, | |
